MetaADEDB 2.0 @ LMMD
2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
(MWYDSXOGIBMAET-UHFFFAOYSA-N)
Structure
SMILES
COc1c(OCCCN2CCOCC2)ccc2c1nc(=NC(=O)c1cnc(nc1)N)n1c2NCC1
Type(s)
Approved; Investigational
ATC code(s)
L01XX61
Molecular Formula:
C23H28N8O4
Molecular Weight:
480.520
Log P:
1.3419
Hydrogen Bond Acceptor:
12
Hydrogen Bond Donor:
2
TPSA:
142.01
CAS Number(s):
1032568-63-0
Synonym(s)
1.
2-amino-N-(7-methoxy-8-(3-morpholinopropoxy)-2,3-dihydroimidazo(1,2-c)quinazolin-4-yl)pyrimidine-5-carboxamide
2.
BAY 80-6946
3.
copanlisib
External Link(s)
MeSHC000589253
PubChem Compound135565596
BindingDB50204093
CHEMBLCHEMBL3218576
DrugBankDB12483
DrugCentral5256
IUPHAR/BPS Guide to PHARMACOLOGY7875
KEGGdr:D10867
Therapeutic Target DatabaseD0S5LD
ZINC68247389
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Product use in unapproved indicationFAERS: 5US FAERS
2PneumoniaFAERS: 4US FAERS
3Blood glucose increasedFAERS: 3US FAERS
4Cardiac ArrestFAERS: 2US FAERS
5ExtravasationFAERS: 2US FAERS
6NeutropeniaFAERS: 2US FAERS
7Oropharyngeal painFAERS: 2US FAERS
8Adverse eventFAERS: 1US FAERS
9Alanine Aminotransferase IncreasedFAERS: 1US FAERS
10ArthralgiaFAERS: 1US FAERS
11Aspartate Aminotransferase IncreasedFAERS: 1US FAERS
12B-cell lymphoma recurrentFAERS: 1US FAERS
13Blood cholesterol increasedFAERS: 1US FAERS
14Blood triglycerides increasedFAERS: 1US FAERS
15Catheter site extravasationFAERS: 1US FAERS
16Catheter site related reactionFAERS: 1US FAERS
17Chest PainFAERS: 1US FAERS
18ChillsFAERS: 1US FAERS
19Disease ProgressionFAERS: 1US FAERS
20DizzinessFAERS: 1US FAERS
21Ear discomfortFAERS: 1US FAERS
22FatigueFAERS: 1US FAERS
23Febrile NeutropeniaFAERS: 1US FAERS
24High density lipoprotein increasedFAERS: 1US FAERS
25Infusion Site ExtravasationFAERS: 1US FAERS
26Injection site erythemaFAERS: 1US FAERS
27Injection site necrosisFAERS: 1US FAERS
28Intentional product misuseFAERS: 1US FAERS
29Lip pruritusFAERS: 1US FAERS
30Low density lipoprotein increasedFAERS: 1US FAERS
31MyalgiaFAERS: 1US FAERS
32NauseaFAERS: 1US FAERS
33NoduleFAERS: 1US FAERS
34PainFAERS: 1US FAERS
35Penile swellingFAERS: 1US FAERS
36Pre-existing condition improvedFAERS: 1US FAERS
37Product administered to patient of inappropriate ageFAERS: 1US FAERS
38Product supply issueFAERS: 1US FAERS
39SinusitisFAERS: 1US FAERS
40Tongue pruritusFAERS: 1US FAERS
41Vessel puncture site painFAERS: 1US FAERS
42Visual ImpairmentFAERS: 1US FAERS
43White blood cell count decreasedFAERS: 1US FAERS
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.